Home Cart 0 Sign in  
X

[ CAS No. 112704-79-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 112704-79-7
Chemical Structure| 112704-79-7
Chemical Structure| 112704-79-7
Structure of 112704-79-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 112704-79-7 ]

Related Doc. of [ 112704-79-7 ]

Alternatived Products of [ 112704-79-7 ]

Product Details of [ 112704-79-7 ]

CAS No. :112704-79-7 MDL No. :MFCD00143263
Formula : C7H4BrFO2 Boiling Point : -
Linear Structure Formula :- InChI Key :ZQQSRVPOAHYHEL-UHFFFAOYSA-N
M.W : 219.01 Pubchem ID :302681
Synonyms :

Calculated chemistry of [ 112704-79-7 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 41.06
TPSA : 37.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.75 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.54
Log Po/w (XLOGP3) : 2.66
Log Po/w (WLOGP) : 2.71
Log Po/w (MLOGP) : 2.79
Log Po/w (SILICOS-IT) : 2.32
Consensus Log Po/w : 2.4

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -3.21
Solubility : 0.135 mg/ml ; 0.000615 mol/l
Class : Soluble
Log S (Ali) : -3.09
Solubility : 0.176 mg/ml ; 0.000804 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.91
Solubility : 0.269 mg/ml ; 0.00123 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.25

Safety of [ 112704-79-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 112704-79-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 112704-79-7 ]
  • Downstream synthetic route of [ 112704-79-7 ]

[ 112704-79-7 ] Synthesis Path-Upstream   1~29

  • 1
  • [ 112704-79-7 ]
  • [ 7746-27-2 ]
Reference: [1] Patent: WO2012/37132, 2012, A1,
  • 2
  • [ 67-56-1 ]
  • [ 112704-79-7 ]
  • [ 72135-36-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2008, vol. 51, # 6, p. 1925 - 1944
  • 3
  • [ 112704-79-7 ]
  • [ 128577-47-9 ]
Reference: [1] European Journal of Medicinal Chemistry, 2018, vol. 150, p. 506 - 524
  • 4
  • [ 51436-99-8 ]
  • [ 112704-79-7 ]
Reference: [1] Tetrahedron, 2004, vol. 60, # 5, p. 1225 - 1228
  • 5
  • [ 7758-19-2 ]
  • [ 57848-46-1 ]
  • [ 112704-79-7 ]
YieldReaction ConditionsOperation in experiment
96% With dihydrogen peroxide In water; acetonitrile 1
4-Bromo-2-fluorobenzoic acid
To a mixture of water (3 ml) and acetonitrile (5 ml) were added Na2HPO4.12H2O (0.11 g), 31percent aqueous hydrogen peroxide (0.34 g, 3.1 mmol), 4-bromo-2-fluorobenzaldehyde (0.41 g, 2.0 mmol) and sodium chlorite (0.27 g, 3.0 mmol), successively, and stirred at room temperature for 1 hour.
The reaction solution was poured into 5percent KHSO4, extracted three times with ethyl acetate and the combined extracts were dried over MgSO4.
The solvent was evaporated under a reduced pressure to give the title compound (0.42 g; 96percent).
1H-NMR(270 MHz, CDCl3) 7.91 (dd, J=8.4, 7.8 Hz, 1H), 7.44-7.36 (m, 2H)
Reference: [1] Patent: US6384033, 2002, B1,
  • 6
  • [ 124-38-9 ]
  • [ 1435-52-5 ]
  • [ 112704-79-7 ]
Reference: [1] European Journal of Organic Chemistry, 2005, # 24, p. 5242 - 5247
  • 7
  • [ 57848-46-1 ]
  • [ 112704-79-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2006, vol. 49, # 2, p. 748 - 759
  • 8
  • [ 872545-52-3 ]
  • [ 112704-79-7 ]
Reference: [1] European Journal of Organic Chemistry, 2005, # 24, p. 5242 - 5247
  • 9
  • [ 1073-06-9 ]
  • [ 112704-79-7 ]
Reference: [1] European Journal of Organic Chemistry, 2005, # 24, p. 5242 - 5247
  • 10
  • [ 67-56-1 ]
  • [ 112704-79-7 ]
  • [ 179232-29-2 ]
YieldReaction ConditionsOperation in experiment
100% for 20 h; Heating / reflux EXAMPLE 9: 4- (8, 8-DIMETHYL-5-P-TOLYL-7, 8-dihydro-2- NAPHTHYLSELANYLETHYNYL)-2-FLUOROBENZOIC acid a. Methyl 4-BROMO-2-FLUOROBENZOATE 5 g (23 mmol) of 4-bromo-2-fluorobenzoic acid are dissolved in methanol with a few drops of sulphuric acid. The reaction medium is refluxed for 20 hours, hydrolysed and extracted with ethyl acetate. A white solid is obtained (5.6 g; yield = 100percent).
96% at 0 - 20℃; for 12 h; To a solution of 4 (13.1 g, 60.0 mmol) in methanol (60 mL) was slowly added SOCk (12 mL) at 0 °C. After stirring overnight (ca. 12 h) at ambient temperature, the solvent was removed under reduced pressure, and the reaction mixture was basified with saturated NaHCCte at 0 °C. Ether (200 mL) was added to the crude mixture, which was washed with saturated NaHCCte (100 mL x 2) and brine (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo. The product mixture was purified by flash chromatography to provide the title product 8 as a white solid (13.4 g, 58 mmol, 96percent). NMR (400 MHz, CDCb) δ 7.86 - 7.78 (m, 1H), 7.39 - 7.30 (m, 2H), 3.92 (s, 2H). 13C NMR (101 MHz, CDCb) δ 164.35, 164.31, 163.06, 160.43, 133.30, 128.10, 128.00, 127.71, 127.67, 120.96, 120.71, 1 17.86, 1 17.76, 52.64. MS (ESI) m/z 233/235 [M+H]+.
93% at 0 - 23℃; for 12.25 h; Step 1 : To a stirred solution of 4-bromo-2-fluorobenzoic acid (15.0 g, 68.49 mmol, 1 eq) in MeOH (150 mL), SOCI2 (23.09 mL, 136.9 mmol, 2 eq) was added at 0 <C for 15 min and the mixture was stirred at RT for 1 2h. The MeOH was evaporated and the residue was diluted with ethyl acetate (250 mL), washed with a saturated aqueous solution of NaHC03, brine (150 mL) and water (150 mL). The ethyl acetate layer was dried over Na2S04, evaporated under vacuum to get methyl 4-bromo-2-fluorobenzoate (15 g, 93percent) as an off white solid (LC-MS purity, 99percent; TLC system: EtOAc/PE (3:7), Rf: 0.8).
93%
Stage #1: With oxalyl dichloride In dichloromethane at 20℃; for 1 h;
Stage #2: at 20℃; for 1 h;
Step 1 (0320) To a solution of compound 3a (50 g, 210 mmol) in DCM (300 mL) was added oxalyl dichloride (40.38 g, 300 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature for lh. Then MeOH (50 ml) was added dropwise, the solution was stirred at room temperature for another lh. The solvent was removed to afford compound 3b (48 g, 93percent).
64% for 20 h; Reflux Example 109AMethyl 4-bromo-2-fluorobenzoic acid; 4-bromo-2-fluorobenzoic acid (30 g, 0.14 mol) was dissolved in methanol with a few drops of sulfuric acid. The reaction medium was refluxed for 20 hours. The cooled reaction mixture was evaporated and the residue partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was separated and washed with brine, dried over sodium sulfate, filtered and evaporated to give methyl 4-bromo-2-fluorobenzoate (20.7 g, yield 64percent) as a white solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm); 3.85 (s, 3H), 7.55-7.58 (m, 1H), 7.70-7.73 (m, 1H), 7.79-7.83 (m, 1H); LC-MS (ESI) m/z: 233 (M+1)+, 235(M+3)+
4851.1 g Reflux; Large scale 4-Bromo-2]DIFFDT_1[-FF]IDDT_21[uorobenzonic acid (2a) (5.0 kg, 22.9 mol) was charged to a 50-L round-bottom glass reaction vessel holding methanol (20.0 L). Concentrated sulfuric acid (500 mL) was added dropwise over 40 min. The reaction mixture was heated under reux for 12 h, poured into ice water (30 L) and the white solid precipitateDDIF]F_T51[ was ltered. The product was dried by heating (less than 50 °C) in an oven overnight to afford 2b as white crystals (4851.1 g, 91.2percent yield). Mp 60.0–61.0 °C; 1IFF]DDT_8[H NMR (400 Hz, DMSO-d6): d 3.85 (t, 3H, J = 8.5 Hz), 7.54–7.57 (dd, 1H, J = 8.8, 1.2 Hz), 7.68–7.71 (dd, 1H, J = 10.4, 1.2 Hz), 7.80–7.84 (t, 1H, J = 8.2 Hz).

Reference: [1] Patent: WO2004/46096, 2004, A2, . Location in patent: Page 38
[2] Organic Process Research and Development, 2011, vol. 15, # 3, p. 565 - 569
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 19, p. 7651 - 7668
[4] Patent: WO2015/48306, 2015, A1, . Location in patent: Page/Page column 88; 112
[5] Patent: WO2013/68461, 2013, A1, . Location in patent: Page/Page column 105; 106; 109
[6] Patent: WO2017/184476, 2017, A1, . Location in patent: Page/Page column 47; 48
[7] Patent: US2009/197863, 2009, A1, . Location in patent: Page/Page column 52-53
[8] Patent: WO2016/123629, 2016, A1, . Location in patent: Paragraph 0214
[9] Chinese Chemical Letters, 2017, vol. 28, # 2, p. 426 - 430
[10] Patent: WO2017/202798, 2017, A1, . Location in patent: Page/Page column 31
  • 11
  • [ 112704-79-7 ]
  • [ 74-88-4 ]
  • [ 179232-29-2 ]
YieldReaction ConditionsOperation in experiment
97% With sodium carbonate In DMF (N,N-dimethyl-formamide) at 20℃; Methyl iodide (1.49 mL, 24 mmol) was added to asuspension of 4-bromo-2-fluorobenzoic acid (4.38 g, 20 mmol) and sodium carbonate (6.36 g, 60 mmol) in dimethylformamide (50 mL), and the mixture was stirred overnight at room temperature. After completion of the reaction, ethyl acetate was added, and the mixture was washed with water and a saturated ammonium chloride aqueous solution. After drying over magnesium sulfate, concentration was carried out to obtain 4.50 g of the desired product as a colorless solid (yield 97percent). ^oH-NMR (ppm in CDC13) d 3.93 (s, 3H), 7.33-7.38 (m, 2H), 7.80-7.85 (m, 1H).
Reference: [1] Patent: WO2004/108683, 2004, A1, . Location in patent: Page 557
[2] Patent: WO2008/134693, 2008, A1, . Location in patent: Page/Page column 78
[3] Patent: US2008/207618, 2008, A1, . Location in patent: Page/Page column 27
[4] Patent: WO2007/41357, 2007, A1, . Location in patent: Page/Page column 47
  • 12
  • [ 112704-79-7 ]
  • [ 18107-18-1 ]
  • [ 179232-29-2 ]
YieldReaction ConditionsOperation in experiment
100% at 0 - 20℃; for 1 h; STEP 1 : To a solution of 4-bromo-2-fluorobenzoic acid (2.0 g, 9.1 mmol) in THF (24 mL) and methanol (6 mL) at 0 °C was added a solution of (trimethylsilyl)diazomethane in hexanes (2.0 M, 5.46 mL, 10.9 mmol). The yellow solution was allowed to gradually warm to room temperature over 1 h. The volatile materials were removed and the residue was treated with aqueous hydrochloric acid (1 M). The aqueous mixture was extracted with ethyl acetate. The organic extract was dried over magnesium sulfate, filtered, and concentrated to provide crude methyl 4- bromo-2-fluorobenzoate (2.7 g, quantitative yield). This material was used in the subsequent step without further purification. 1H NMR (400 MHz, CDCl3): 7.85-7.81 (m, IH), 7.38-7.33 (m, 2H), 3.93 (s, 3H); MS (EI) for C8H6BrFO2: 232, 234 (MH+).
Reference: [1] Patent: WO2009/55077, 2009, A1, . Location in patent: Page/Page column 447
[2] Journal of Medicinal Chemistry, 2014, vol. 57, # 6, p. 2334 - 2356
[3] Patent: WO2010/65865, 2010, A2, . Location in patent: Page/Page column 285-286
  • 13
  • [ 112704-79-7 ]
  • [ 179232-29-2 ]
YieldReaction ConditionsOperation in experiment
52% With chloro-trimethyl-silane In methanol for 12 h; Reflux Example 35A
Methyl 4-bromo-2-fluorobenzoate
A solution of 8 g (36.53 mmol) of 4-bromo-2-fluorobenzoic acid in 44 ml of methanol is mixed with 0.46 ml (3.65 mmol) of chlorotrimethylsilane and heated to reflux for 12 h.
The mixture is then concentrated and the residue is taken up in cyclohexane and filtered through silica gel. 4.49 g (19.25 mmol, 52percent yield) of a white solid are obtained.
Rf (cyclohexane/ethyl acetate 2:1): 0.5.
1H-NMR (200 MHz, DMSO-d6, δ/ppm): 7.84 (1H, t), 7.75 (1H, dd), 7.58 (1H, dd), 3.88 (3H, s).
MS (EI): 232 (M+).
Reference: [1] Patent: US2009/227640, 2009, A1, . Location in patent: Page/Page column 42
[2] Patent: US2017/313683, 2017, A1,
  • 14
  • [ 112704-79-7 ]
  • [ 625446-22-2 ]
Reference: [1] Patent: WO2009/151991, 2009, A1,
[2] Patent: US2011/263559, 2011, A1,
[3] Patent: US2012/59030, 2012, A1,
[4] Patent: EP2455380, 2012, A1,
[5] Patent: WO2012/37132, 2012, A1,
[6] Patent: WO2015/162538, 2015, A1,
  • 15
  • [ 112704-79-7 ]
  • [ 259750-61-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 22, p. 3983 - 3987
[2] Patent: US2011/263559, 2011, A1,
[3] Patent: WO2017/81483, 2017, A1,
  • 16
  • [ 64-17-5 ]
  • [ 112704-79-7 ]
  • [ 474709-71-2 ]
YieldReaction ConditionsOperation in experiment
90% With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 20 h; Step 1.
Preparation of ethyl 4-bromo-2-fluorobenzoate
To a stirred solution of 4-bromo-2-fluorobenzoic acid (1.50 g, 6.85 mmol) in DCM (26.0 mL) was added EDCI (1.60 g, 8.35 mmol), DMAP (130 mg, 1.06 mmol), and EtOH (2.00 mL) at room temperature.
After being stirred for 20 hours at room temperature, the reaction mixture was washed with water and brine.
The organic phase was dried over Na2SO4, filtered and concentrated in vacuo.
The residue was purified by column chromatography on SiO2 (Hexanes/EtOAc=1/5) to give the desired product (1.52 g, 90percent) as a colorless oil. 1H-NMR (400 MHz, CDCl3) δ 1.39 (3H, t, J=6.8 Hz), 4.39 (2H, q, J=6.8 Hz), 7.32-7.37 (2H, m), 7.80-7.84 (1H, m).
3.3 g With thionyl chloride In ethanol at 0 - 70℃; A) ethyl 4-bromo-2-fluorobenzoate [0880] To a solution of 4-bromo-2-fluorobenzoic acid (3.0 g) in ethanol (20 mL) was added thionyl chloride (2.0 mL) at 0°C, and the mixture was stirred overnight at 70°C. To the reaction mixture was added saturated aqueous sodium hydrogencarbonate solution, the mixture was concentrated under reduced pressure, and the residue was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (3.30 g). 1H NMR (300 MHz, CDCl3) δ 1.39 (3H, t, J = 7.2 Hz), 4. 39 (2H, q, J = 7.2 Hz), 7.30-7.40 (2H, m), 7.82 (1H, dd, J = 8.7, 7.9 Hz).
2 g Reflux Compound 4-bromo-2-fluoro-benzoic acid (2g, 9.1mmoL) was dissolved in 20mL of ethanol was added 2mL of concentrated sulfuric acid and refluxed overnight, then rotating the ethanol with sodium bicarbonate to about pH = 8, ethyl ester extraction, the organic phase spin dry vested 2g product. The above product (100mg, 0.4mmol) and piperazine (40mg, 0.48mmol) were mixed in 5mL of toluene, under nitrogen, was added successively cesium carbonate (188mg, 0.6mmoL), 10mg of bis (tri-t-butylphosphine) palladium, followed by stirring at 130 microwave 6 hours, and then distilled toluene, was added 20mL of water and 20mL of dichloromethane, the organic phase was dried over sodium sulfate, filtered, and the filtrate worked spin column to give 2-fluoro-4- (piperazin - 1- yl) benzoic acid ethyl ester (35mg).
Reference: [1] Patent: US2012/53180, 2012, A1, . Location in patent: Page/Page column 29
[2] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 12, p. 1207 - 1212
[3] Patent: WO2006/34491, 2006, A2, . Location in patent: Page/Page column 119-120
[4] Patent: EP2857400, 2015, A1, . Location in patent: Paragraph 0880
[5] Patent: CN105712928, 2016, A, . Location in patent: Paragraph 0176; 0177
[6] RSC Advances, 2018, vol. 8, # 12, p. 6306 - 6314
  • 17
  • [ 112704-79-7 ]
  • [ 74-89-5 ]
  • [ 749927-69-3 ]
YieldReaction ConditionsOperation in experiment
93%
Stage #1: With thionyl chloride In 1,2-dimethoxyethane at 0 - 50℃;
Stage #2: at 35℃; for 0.5 h;
Compound 9 (2.2 g, 10 mmol) was added to anhydrous ethylene glycol dimethyl ether (20 mL).The solution was cooled to 0 ° C, and thionyl chloride (1.5 g, 13 mmol) was slowly added under stirring. The reaction was mildly exothermic, and the temperature of the solution did not exceed 5 ° C during the addition of thionyl chloride. After reacting at 0 ° C for 1 h, the solution is reacted at 50 ° C for not less than 6 h or TLC monitoring shows that the reaction is complete, the solution temperature is lowered to 25 ° C, and it will be dissolved in ethylene glycol dimethyl ether (5 mL).A solution of methylamine (0.9 g, 30 mmol) was slowly added dropwise thereto, and the mixed solution was reacted at 35 ° C for 0.5 h or TLC monitoring showed that the reaction was completed, the reaction was stopped, and saturated brine (15 mL) was added, and ethyl acetate (2) *15mL), extracted, layered, combined with organic layer, dried over anhydrous sodium sulfate, filtered.Concentration and drying gave a white solid in a yield of 88-93percent.
74% With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 16 h; Step 1 : 4-Bromo-2-fluoro-N-methylbenzamide To a 100 niL flask is added 4-bromo-2-fluorobenzonic acid (3.0 g, 13.7 mmol), 2 M methylamine (34.3 mL, 68.5 mmol), EDCI (6.6 g, 34.25 mmol), HOBt (2.8 g, 20.6 mmol), jV,jV-diisopropylethylamine, and DMF (50 mL). The reaction mixture is stirred at room temperature for 16 hrs. Then water (50 mL) is added. The aqueous phase is isolated and extracted with ethyl acetate (3 X 50 mL). The combined organic phases are dried over anhydrous sodium sulfate, filtered, and concentrated. The residue is purified on a silica gel flash chromatography with ethyl acetate/petroleum ether (1 :3 ) to yield the titled compound as a white solid (2.34 g, 74percent yield). (MS: [M+l] 232)
32% With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane for 24 h; 4-Bromo-2-fluoro-N-methyl-benzamide A solution of 4-bromo-2-fluorobenzoic acid (0.8g, 3. 7MMOL), methylamine (3.65mL, 7. 3MMOL), EDC (1.4g, 7. 3MMOL), triethylamine (1. 0ML, 7. 3MMOL) dissolved in CH2CI2 (15ML) was stirred under N2 for 24h. The reaction mixture was partitioned between 1 N HCI and EtOAc. The organic layers were washed with saturated NAHC03, brine, dried over dried over NA2SO4AND concentrated. The residue was purified by silica gel chromatography (40percent EtOAc in hexanes) to give the title compound as a white solid (0.27g, 32percent). H NMR (CDC13) : 5 3.03 (d, 3H, J= 6.0 Hz), 6.68 (BR S, 1H), 7.32 (d, 1H, J= 11.3 Hz), 7.42 (d, 1H, J= 10.2 Hz), 8.01 (t, 1H, J= 8.5 Hz).
32% With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane for 24 h; A solution of 4-bromo-2-fluorobenzoic acid (0.8 g, 3.7 mmol), methylamine (3.65 mL, 7.3 mmol), EDC (1.4 g, 7.3 mmol), triethylamine (1.0 mL, 7.3 mmol) dissolved in CH2Cl2(15 mL) was stirred under N2 for 24 h. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layers were washed with saturated NaHCO3, brine, dried over dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography (40percent EtOAc in hexanes) to give the title compound as a white solid (0.27 g, 32percent). 1H NMR (CDCl3): δ 3.03 (d, 3H, J=6.0 Hz), 6.68 (br s, 1H), 7.32 (d, 1H, J=11.3 Hz), 7.42 (d, 1H, J=10.2 Hz), 8.01 (t, 1H, J=8.5 Hz).

Reference: [1] Patent: CN108329236, 2018, A, . Location in patent: Paragraph 0026; 0035; 0036; 0038
[2] Patent: WO2014/32498, 2014, A1, . Location in patent: Page/Page column 9
[3] Patent: WO2004/74270, 2004, A2, . Location in patent: Page 44
[4] Patent: US2005/176701, 2005, A1, . Location in patent: Page/Page column 21
[5] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 24, p. 6486 - 6489
  • 18
  • [ 112704-79-7 ]
  • [ 749927-69-3 ]
YieldReaction ConditionsOperation in experiment
100% With (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 2 h; Compound 49: (4-Bromo-2-fluoro-benzyl)-methyl-amine. (1029) A mixture of 4-bromo-2-fluorobenzoic acid (1.0 equiv.), methylamine hydrochloride (1.1 equiv.), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (1.1 equiv.) and diisopropylethylamine (3.3 equiv.) in dichloromethane (0.20 mol.L-1) was stirred for 2 hours at room temperature. The reaction mixture was hydrolyzed and extracted twice with dichloromethane. The organic layers were combined, washed with brine, dried over MgSO4, concentrated, and purified by flash column chromatography on silica gel (10percent to 50percent EtOAc in cyclohexane) to afford the intermediate methylamide as a white solid in quantitative yield.
Reference: [1] Patent: WO2017/81483, 2017, A1, . Location in patent: Page/Page column 228-229
  • 19
  • [ 112704-79-7 ]
  • [ 749927-69-3 ]
Reference: [1] Patent: WO2011/106570, 2011, A1,
[2] Patent: WO2016/5875, 2016, A1,
[3] Patent: CN104016924, 2016, B,
  • 20
  • [ 112704-79-7 ]
  • [ 114897-92-6 ]
Reference: [1] Patent: US2013/197217, 2013, A1,
  • 21
  • [ 112704-79-7 ]
  • [ 869569-77-7 ]
Reference: [1] Patent: WO2009/151991, 2009, A1,
  • 22
  • [ 112704-79-7 ]
  • [ 85070-58-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 6, p. 2334 - 2356
  • 23
  • [ 112704-79-7 ]
  • [ 299937-74-9 ]
Reference: [1] Patent: US2015/259357, 2015, A1,
  • 24
  • [ 112704-79-7 ]
  • [ 75-65-0 ]
  • [ 889858-12-2 ]
YieldReaction ConditionsOperation in experiment
95.5% With dmap; di-<i>tert</i>-butyl dicarbonate In tetrahydrofuran at 80℃; for 13 h; Step 1 : Preparation of tert-butyl 4-bromo-2-fluoro-benzoate To a solution of 4-bromo-2-fluoro-benzoic acid (100.0 g, 0.46 mol) in THF/t-BuOH (800 mL/400 mL) was added Boc20 (150.0 g, 0.69 mol) and DMAP (5.6 g, 46.0 mmol), the mixture was stirred at 80°C for 13h. TLC (PE:EtOAc=10:1 ) showed the reaction was completed. After removal of the solvent, the residue was dissolved in water and extracted with EtOAc (500 mL x 3), the organic layer was dried over Na2S04 and concentrated to give the crude product, which was purified by column chromatography (PE:EtOAc=100:1 ) to give the title compound (120.0 g, 95.5percent) as a colorless oil. H-NMR (400 MHz, CDCI3): δ = 7.69 - 7.78 (m, 1 H) 7.26 - 7.34 (m, 2 H) 1 .58 (s, 9 H)
80%
Stage #1: With oxalyl dichloride; N,N-dimethyl-formamide In tetrahydrofuran at 0 - 20℃; for 1.5 h;
Stage #2: With pyridine In dichloromethane at 20℃; for 64 h;
Step 1.
tert-Butyl 4-bromo-2-fluorobenzoate
To a stirred solution of 4-bromo-2-fluorobenzoic acid (60 g, 274 mmol) in anhydrous THF (700 mL) at 0° C. was added DMF (2 mL) followed by oxalyl chloride (48 mL, 548 mmol) portionwise over 1 hour.
The mixture was stirred at 0° C. for 30 min, and then at room temperature for 1 hour.
The solvent was removed under reduced pressure, and the residue dissolved in DCM (700 mL).
tert-Butyl alcohol (97 g, 1315 mmol) and pyridine (150 mL) were added, and the reaction mixture was stirred at room temperature for 64 h.
The mixture was transferred to a separating funnel and washed with water (400 mL), 2 N NaOH aqueous solution (400 mL) and brine (2*200 mL), dried over magnesium sulfate, filtered and concentrated under vacuum.
The residue was purified by flash chromatography on silica gel (0 to 5percent ethyl acetate in heptane over 30 min) to give tert-butyl 4-bromo-2-fluorobenzoate (60 g, 80percent) as an oil. LCMS (m/z): 218/220 (MH+ (-tBu)), 1.11 min; 1H NMR (500 MHz, CDCl3) δ ppm 7.81-7.71 (m, 1H) 7.39-7.30 (m, 2H) 7.29 (s, 1H) 1.68-1.55 (m, 9H).
74%
Stage #1: With oxalyl dichloride In dichloromethane; N,N-dimethyl-formamide at 20℃; for 5 h;
Stage #2: With pyridine In tetrahydrofuran at 0 - 50℃; for 23 h;
4-Bromo-2-fluorobenzoic acid (1 ) (10 g, 46 mmol) was suspended in DCM (100 mL), treated with oxalyl chloride (12.0 mL, 137 mmol) followed by DMF (36 μ, 0.46 mmol) and the mixture was stirred at RT for 5 h. The mixture was concentrated in vacuo to give a yellow oil which was redissolved in THF and added dropwise to a mixture of pyridine (5.5 mL, 68 mmol) and 'BuOH (8.7 mL, 91 mmol) in THF (100 mL) at 0°C. The mixture was then warmed to RT, stirred at RT for 18 h, then at 50°C for 5 h. The mixture was cooled to RT, concentrated in vacuo and the residue was purified by silica gel chromatography (220 g, 0-10percent EtOAc in isohexane) to afford the title compound (2) (0862) (9.3 g, 74percent) as a colourless oil: 1 H NMR (400 MHz, CDCI3) δ: 7.76 - 7.72 (1 H, m), 7.34 - 7.28 (2H, m), 1 .58 (9H, s)
Reference: [1] Patent: WO2016/102482, 2016, A1, . Location in patent: Page/Page column 114
[2] Patent: US9242996, 2016, B2, . Location in patent: Page/Page column 248; 251
[3] Patent: WO2016/97004, 2016, A1, . Location in patent: Page/Page column 108
  • 25
  • [ 24424-99-5 ]
  • [ 112704-79-7 ]
  • [ 889858-12-2 ]
Reference: [1] Patent: WO2015/110467, 2015, A1, . Location in patent: Page/Page column 14
  • 26
  • [ 112704-79-7 ]
  • [ 115-11-7 ]
  • [ 889858-12-2 ]
Reference: [1] Patent: US9242996, 2016, B2, . Location in patent: Page/Page column 382; 383
  • 27
  • [ 112704-79-7 ]
  • [ 801303-32-2 ]
Reference: [1] Patent: CN105936633, 2016, A,
  • 28
  • [ 112704-79-7 ]
  • [ 1242157-15-8 ]
Reference: [1] Patent: WO2015/949, 2015, A1,
  • 29
  • [ 112704-79-7 ]
  • [ 1289942-66-0 ]
Reference: [1] Patent: WO2011/106570, 2011, A1,
[2] Patent: WO2016/5875, 2016, A1,
[3] Patent: CN104016924, 2016, B,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 112704-79-7 ]

Enzalutamide Related Intermediates

Chemical Structure| 749927-69-3

[ 749927-69-3 ]

4-Bromo-2-fluoro-N-methylbenzamide

Chemical Structure| 915087-25-1

[ 915087-25-1 ]

4-Amino-2-fluoro-N-methylbenzamide

Chemical Structure| 654-70-6

[ 654-70-6 ]

4-Cyano-3-trifluoromethylaniline

Chemical Structure| 403-24-7

[ 403-24-7 ]

2-Fluoro-4-nitrobenzoic acid

Chemical Structure| 62-57-7

[ 62-57-7 ]

2-Amino-2-methylpropanoic acid

Related Functional Groups of
[ 112704-79-7 ]

Fluorinated Building Blocks

Chemical Structure| 415965-24-1

[ 415965-24-1 ]

4-Bromo-2-fluoro-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 146328-85-0

[ 146328-85-0 ]

5-Bromo-2-fluorobenzoic acid

Similarity: 0.98

Chemical Structure| 289039-48-1

[ 289039-48-1 ]

4,5-Dibromo-2-fluorobenzoic acid

Similarity: 0.97

Chemical Structure| 28314-82-1

[ 28314-82-1 ]

4-Bromo-2,5-difluorobenzoic acid

Similarity: 0.95

Chemical Structure| 515135-65-6

[ 515135-65-6 ]

5-Bromo-2-fluoro-4-methylbenzoic acid

Similarity: 0.95

Aryls

Chemical Structure| 415965-24-1

[ 415965-24-1 ]

4-Bromo-2-fluoro-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 146328-85-0

[ 146328-85-0 ]

5-Bromo-2-fluorobenzoic acid

Similarity: 0.98

Chemical Structure| 289039-48-1

[ 289039-48-1 ]

4,5-Dibromo-2-fluorobenzoic acid

Similarity: 0.97

Chemical Structure| 28314-82-1

[ 28314-82-1 ]

4-Bromo-2,5-difluorobenzoic acid

Similarity: 0.95

Chemical Structure| 515135-65-6

[ 515135-65-6 ]

5-Bromo-2-fluoro-4-methylbenzoic acid

Similarity: 0.95

Bromides

Chemical Structure| 415965-24-1

[ 415965-24-1 ]

4-Bromo-2-fluoro-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 146328-85-0

[ 146328-85-0 ]

5-Bromo-2-fluorobenzoic acid

Similarity: 0.98

Chemical Structure| 289039-48-1

[ 289039-48-1 ]

4,5-Dibromo-2-fluorobenzoic acid

Similarity: 0.97

Chemical Structure| 28314-82-1

[ 28314-82-1 ]

4-Bromo-2,5-difluorobenzoic acid

Similarity: 0.95

Chemical Structure| 515135-65-6

[ 515135-65-6 ]

5-Bromo-2-fluoro-4-methylbenzoic acid

Similarity: 0.95

Carboxylic Acids

Chemical Structure| 415965-24-1

[ 415965-24-1 ]

4-Bromo-2-fluoro-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 146328-85-0

[ 146328-85-0 ]

5-Bromo-2-fluorobenzoic acid

Similarity: 0.98

Chemical Structure| 289039-48-1

[ 289039-48-1 ]

4,5-Dibromo-2-fluorobenzoic acid

Similarity: 0.97

Chemical Structure| 28314-82-1

[ 28314-82-1 ]

4-Bromo-2,5-difluorobenzoic acid

Similarity: 0.95

Chemical Structure| 515135-65-6

[ 515135-65-6 ]

5-Bromo-2-fluoro-4-methylbenzoic acid

Similarity: 0.95